Scienture Holdings

SCNX · NASDAQ

$3.05+$0.00 (+0.00%)TodayMarket closed · Oct 21, 4:32 AM ET

Prev close $3.05

Latest news

NewsOct 13, 7:45 AM ETVandana Singh
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
NewsOct 2, 7:46 AM ETVandana Singh
EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
NewsOct 1, 1:57 AM ETTanya Rawat
Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened
NewsSep 9, 8:06 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsAug 12, 7:46 AM ETVandana Singh
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US
NewsJul 10, 4:27 AM ETMohd Haider
Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why
NewsJun 16, 8:50 AM ET
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose
NewsJun 9, 7:46 AM ETVandana Singh
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch
Press releaseApr 6, 8:05 AM ETGlobe Newswire
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
NewsMar 30, 1:05 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsMar 30, 7:46 AM ETVandana Singh
EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025
NewsMar 17, 5:12 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsMar 12, 1:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsMar 11, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsMar 11, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsMar 11, 7:46 AM ETVandana Singh
EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market
NewsMar 5, 4:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsJan 14, 7:51 AM ETVandana Singh
EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment
NewsNov 13, 7:50 AM ETVandana Singh
EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction
NewsNov 4, 12:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsNov 4, 7:51 AM ETVandana Singh
EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives
NewsOct 24, 10:09 AM ETAvi Kapoor
Nasdaq Surges 1%; Procter & Gamble Posts Upbeat Earnings
NewsOct 23, 9:50 PM ETShivdeep Dhaliwal
Intel, Scienture Holdings, Ford, Deckers, And Super Micro Computer: Why These 5 Stocks Are On Investors' Radars Today
NewsOct 23, 3:23 PM ETAvi Kapoor
Crude Oil Surges 5%; American Airlines Shares Jump After Q3 Results
NewsOct 23, 1:14 PM ETAlex Perry
Scienture Holdings Stock Is Soaring Thursday: What's Fueling The Momentum?
NewsOct 23, 1:07 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsOct 23, 9:56 AM ETAvi Kapoor
Dow Gains 50 Points; Tesla Shares Slide After Q3 Earnings
Press releaseOct 16, 9:00 AM ETGlobe Newswire
SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers
NewsOct 1, 8:46 AM ETMohit Manghnani
EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions
Press releaseMay 22, 8:05 AM ETGlobe Newswire
SCIENTURE Announces Executive Leadership Transition
Press releaseMay 19, 8:05 AM ETGlobe Newswire
SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.
NewsApr 3, 8:33 AM ET
Scienture Holdings Releases Annual Letter To Shareholders
Press releaseApr 3, 8:26 AM ETGlobe Newswire
Scienture Holdings, Inc. Issues Annual Letter to Shareholders
Press releaseDec 17, 8:05 AM ETGlobe Newswire
Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability

EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions

Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US

Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why

FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose

EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch

Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead

12 Health Care Stocks Moving In Monday's Intraday Session

EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market

12 Health Care Stocks Moving In Thursday's After-Market Session

EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment

EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction

12 Health Care Stocks Moving In Tuesday's Intraday Session

EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives

Nasdaq Surges 1%; Procter & Gamble Posts Upbeat Earnings

Intel, Scienture Holdings, Ford, Deckers, And Super Micro Computer: Why These 5 Stocks Are On Investors' Radars Today

Crude Oil Surges 5%; American Airlines Shares Jump After Q3 Results

Scienture Holdings Stock Is Soaring Thursday: What's Fueling The Momentum?

12 Health Care Stocks Moving In Thursday's Intraday Session

Dow Gains 50 Points; Tesla Shares Slide After Q3 Earnings

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions

SCIENTURE Announces Executive Leadership Transition

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

Scienture Holdings Releases Annual Letter To Shareholders

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025